Keyphrases
Cystic Fibrosis
100%
Acute Respiratory Distress Syndrome
26%
Pulmonary Fibrosis
22%
Pseudomonas Aeruginosa (P. aeruginosa)
21%
Transforming Growth Factor-β
20%
Cystic Fibrosis Transmembrane Conductance Regulator
20%
Acute Lung Injury
19%
Forced Expiratory Volume in 1 Second (FEV1)
17%
Fibrosis
16%
Lung Fibrosis
14%
Lung
11%
Alveolar Macrophages
11%
Clinical Trials
10%
Ivacaftor
9%
F508del
9%
Systemic Sclerosis
9%
Monocyte-derived Cells
9%
Type III Secretion
9%
Pulmonary Exacerbation
9%
Chronic Infection
9%
Peroxisome Proliferator-activated Receptor
8%
Bronchoalveolar Lavage Fluid
8%
Idiopathic Pulmonary Fibrosis
7%
Clinical Outcomes
7%
Adult Patients
7%
Fibroproliferative
7%
Lung Injury
6%
Therapeutic Target
6%
Gene Expression
6%
Tezacaftor
6%
Reactive Oxygen Species
6%
COVID-19
6%
Thrombosis
5%
Metformin
5%
Mitochondrial Electron Transport
5%
Air Pollution
5%
Metabolism
5%
Sedation
5%
Fibrogenesis
5%
Bortezomib
5%
Vignettes
5%
Gene Therapy
5%
Aminoglycosides
5%
Pulmonary Artery Catheter
5%
Catenin
5%
Acute Severe Asthma
5%
Pneumonia
5%
Genotype
5%
Alveolar Epithelial Cells
5%
Smad
5%
Medicine and Dentistry
Cystic Fibrosis
60%
Acute Respiratory Distress Syndrome
25%
Lung
24%
Diseases
21%
Pulmonary Fibrosis
19%
Cystic Fibrosis Transmembrane Conductance Regulator
17%
Acute Lung Injury
14%
Cancer Growth Factor
12%
Fibrosis
10%
Clinical Trial
10%
Ivacaftor
9%
Breathing
9%
Injury
9%
Lung Fibroblast
8%
Exhalation
8%
Bronchoalveolar Lavage Fluid
7%
Peroxisome Proliferator Activated Receptor
7%
Patient with Cystic Fibrosis
7%
Pseudomonas aeruginosa
6%
Tezacaftor
6%
Fibrinogen
6%
Reactive Oxygen Species
6%
Artificial Respiration
6%
Placebo
6%
Severe Asthma
5%
Pulmonary Artery Catheter
5%
Cell Death
5%
Alveolar Macrophage
5%
Intubation
5%
Continuous Positive Airway Pressure
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
58%
Lung Fibrosis
18%
Adult Respiratory Distress Syndrome
18%
Fibrosis
17%
Acute Lung Injury
16%
Cancer Growth Factor
15%
Disease
15%
Cystic Fibrosis Transmembrane Conductance Regulator
14%
Clinical Trial
12%
Ivacaftor
11%
Reactive Oxygen Metabolite
10%
Fibrinogen
9%
Pseudomonas aeruginosa
9%
Aminoglycoside
8%
Lung Disease
8%
Peroxisome Proliferator Activated Receptor
7%
Infection
7%
Tezacaftor
6%
Bortezomib
5%
Pulmonary Hypertension
5%